gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · OBIOHealthcareSurgical Instruments

Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO)

$6.08+9.35%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$6.08▲ 53.92% in range
Nov 3, 2025Low $3.49 · High $6.35Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Orchestra BioMed Holdings closed at $6.08 on Nov 4, up 9.35%, 4.3% below its 52-week closing high. Volume of 154.3K shares was 0.47× its 20-day average (below normal).

Split-adjusted performance: +4.1% over one month, +47.9% over six months, +53.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $88K, down 89.5% from a year earlier, with a net margin of -27362.5%.

Short interest was 2.6M shares at the Oct 15 settlement (8.1% of float, 9.7 days to cover).

Market cap$365.4M60.1M shares
Revenue · quarter$88.0K−89.5% YoY
Diluted EPS$-0.38—
P/E · TTM—P/S 11.4×
Net margin-27,362.5%Gross 71.6%
Dividend yieldNone
52-week range3.49 – 6.35−4.3% from high
Volume154.3K0.47× 20-day avg
Volatility · 60d65.5%Annualised
Short % of float8.1%9.7 days to cover
Net cash$75.1MCash $110.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.5%1M +4.1%3M +46.5%6M +47.9%YTD +46.5%1Y +53.9%3Y +31.6%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum83
Revenue growth0
Net margin0
Value (low P/E)—
Size51

Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.

Short interest

Details →
Shares short2.6M+0.2% vs prior
Days to cover9.7Settled Oct 15
% of float8.1%
Short vol. 10d66.2%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
OBIOOrchestra BioMed Holdings$6.08+9.35%+47.9%−89.5%−27362.5%—$365.4M
MOBIMobia Medical$11.08+11.17%——−155.8%—$369.0MCompare
EMBCEmbecta$6.62+8.80%+85.8%−8.1%7.8%4.3$374.8MCompare
OFIXOrthofix Medical Inc. Common Stock (DE)$9.63+9.93%−21.0%+3.8%−7.5%—$392.3MCompare
CLPTClearPoint Neuro$10.30+6.08%−10.2%+36.3%−61.8%—$330.2MCompare
CARLCarlsmed$15.96+10.83%+62.2%—−55.5%—$435.8MCompare
SIShoulder Innovations$21.14+6.66%+64.0%—−59.1%—$440.1MCompare
TMCITreace Medical Concepts$4.58+6.89%+137.0%−4.2%−35.0%—$297.5MCompare
SSIISS Innovations International$2.26−2.92%−44.4%+39.4%−19.1%—$453.5MCompare

News about Orchestra BioMed Holdings

All news →
Orchestra BioMed Joins Russell 3000® and Russell 2000® IndexesGlobeNewswire Inc. · Jun 29, 2026▲ Positive

Quick answers

What does Orchestra BioMed Holdings do?
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality.
What is OBIO's market cap?
$365.44M, based on the Nov 4 close of $6.08.
Does Orchestra BioMed Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of OBIO is sold short?
2.6M shares, 8.1% of float, as of Oct 15, 2026.
What sector is OBIO in?
Healthcare, in the Surgical Instruments industry.

About Orchestra BioMed Holdings

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

HQ: New Hope, PA86 employeesListed Jan 27, 2023orchestrabiomed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology